Gozanertinib (DBPR112) is a highly potent, selective inhibitor of EGFR mutant L858R/T790M (IC50=48 nM) and exon 20 insertion mutations.
DBPR112 inhibited HCC827 cell growth with IC50 of 25 nM, exhibited tenfold potency better than the third-generation inhibitor, osimertinib, against EGFR and HER2 exon 20 insertion mutations.
DBPR112 demonstrated significant antitumor efficacy in in vivo xenograft models.
